Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through two segments, the United States and International. The United States segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides central specialty pharmacy services and mail services. As of August 31, 2021, this segment operated 8,965 retail stores under the Walgreens and Duane Reade brands in the United States; and five specialty pharmacies. The International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty retail stores and optical practices, as well as through boots.com and an integrated mobile application. It also engages in pharmaceutical wholesaling and distribution business in Germany. As of August 31, 2021, this segment operated 4,031 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 548 optical practices, including 160 on a franchise basis. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.
Walgreens Boots Alliance Stock Down 6.4 %
Shares of NASDAQ:WBA opened at $38.24 on Friday. Walgreens Boots Alliance has a 52 week low of $36.57 and a 52 week high of $55.00. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.43 and a current ratio of 0.78. The company's fifty day moving average is $39.38 and its 200-day moving average is $43.42. The company has a market capitalization of $33.05 billion, a PE ratio of 6.17, a P/E/G ratio of 1.67 and a beta of 0.60.
Walgreens Boots Alliance (NASDAQ:WBA - Get Rating) last issued its earnings results on Thursday, June 30th. The pharmacy operator reported $0.96 EPS for the quarter, beating the consensus estimate of $0.95 by $0.01. Walgreens Boots Alliance had a net margin of 4.00% and a return on equity of 16.20%. The company had revenue of $32.60 billion for the quarter, compared to the consensus estimate of $32.23 billion. During the same quarter in the previous year, the company earned $1.51 EPS. The firm's revenue for the quarter was down 4.2% compared to the same quarter last year. Equities research analysts predict that Walgreens Boots Alliance will post 5.02 earnings per share for the current fiscal year.
Walgreens Boots Alliance Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, September 9th. Investors of record on Friday, August 19th will be given a dividend of $0.48 per share. This is an increase from Walgreens Boots Alliance's previous quarterly dividend of $0.48. The ex-dividend date is Thursday, August 18th. This represents a $1.92 annualized dividend and a yield of 5.02%. Walgreens Boots Alliance's dividend payout ratio is 30.81%.
Analysts Set New Price Targets
A number of brokerages recently issued reports on WBA. Morgan Stanley dropped their target price on shares of Walgreens Boots Alliance from $43.00 to $39.00 and set an "underweight" rating on the stock in a research report on Wednesday, July 6th. StockNews.com raised shares of Walgreens Boots Alliance from a "hold" rating to a "buy" rating in a research report on Friday. Truist Financial dropped their target price on shares of Walgreens Boots Alliance from $50.00 to $42.00 and set a "hold" rating on the stock in a research report on Friday, July 1st. Cowen dropped their target price on shares of Walgreens Boots Alliance to $49.00 in a research report on Thursday, June 9th. Finally, TheStreet lowered shares of Walgreens Boots Alliance from a "b-" rating to a "c+" rating in a research report on Monday, May 2nd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $46.25.